<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03934177</url>
  </required_header>
  <id_info>
    <org_study_id>18557</org_study_id>
    <nct_id>NCT03934177</nct_id>
  </id_info>
  <brief_title>Impact of Blueberry Consumption on Gastrointestinal Health</brief_title>
  <official_title>Impact of Blueberry Consumption on Intestinal Permeability, Gut Microbiota, and Gut-Derived Inflammation in Individuals With Elevated Risk of a Pro-Inflammatory Gut Milieu</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nebraska Lincoln</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Nebraska</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Nebraska Lincoln</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the impact of blueberry consumption on markers of gastrointestinal&#xD;
      health including gut microbiota, intestinal permeability, and gut-derived inflammation in&#xD;
      those vulnerable to a unhealthy gut milieu. All participants will consume a blueberry powder&#xD;
      and a placebo in this crossover study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The commensal bacteria that reside in the human gut, known as the gut microbiota, is a&#xD;
      complex system that modulates local gut homeostasis and systemic biological processes.&#xD;
      Several environmental factors have been shown to influence the gut milieu (including&#xD;
      microbiota), and thus both gastrointestinal and host health. Relevant to the current proposal&#xD;
      is the influence of body weight, diet, and circadian rhythms. In the current study, the&#xD;
      investigators propose to use these common disruptors of gastrointestinal health through&#xD;
      recruiting obese shift workers with a low-fiber diet to identify if these disrupted&#xD;
      individuals can benefit from blueberry intake. Specifically, the study objectives are to&#xD;
      determine if 24 g whole blueberry powder consumed daily can beneficially modify intestinal&#xD;
      permeability, gut microbiota, microbial metabolites, and both gut-derived and systemic&#xD;
      inflammation in those most susceptible to a pro-inflammatory milieu. This will be&#xD;
      accomplished through a 14-week crossover study in which 28 individuals will be randomized by&#xD;
      treatment group order to 4 weeks of whole blueberry powder and placebo powder, with a 4-week&#xD;
      wash out in between the treatment periods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">March 26, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This 14-week crossover study includes 4 weeks for each of the two supplementation periods (blueberries and placebo), with a 4-week wash out between.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participants, investigators, and statistician will blinded to treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>intestinal permeability</measure>
    <time_frame>28 days</time_frame>
    <description>urinary sugar measurement by gas chromatography (GC): Sucralose, lactulose, mannitol, sucrose as a percent of oral dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiota</measure>
    <time_frame>28 days</time_frame>
    <description>Microbiota composition through shotgun sequencing. Composition includes relative abundance of all microbes in stool.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbial metabolites</measure>
    <time_frame>28 days</time_frame>
    <description>Quantity of stool short-chain fatty acid (butyrate, propionate, acetate) per dry stool weight by gas chromatography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut-derived/systemic inflammation</measure>
    <time_frame>28 days</time_frame>
    <description>Concentration of serum lipopolysaccharide (LPS), LPS-binding protein (LBP), and interleukin-6 (IL6)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Obesity</condition>
  <condition>Circadian Dysregulation</condition>
  <arm_group>
    <arm_group_label>Blueberry powder</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 weeks of supplementation of 24 g whole blueberry powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo powder</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4 weeks of supplementation of 24 g placebo powder (maltodextrin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Blueberry powder</intervention_name>
    <description>Dried, powdered blueberries will be consumed at 24 g/day in two divided doses at least 4 hours apart.</description>
    <arm_group_label>Blueberry powder</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo powder</intervention_name>
    <description>A placebo consisting maltodextrin will be consumed at 24 g/day in two divided doses at least 4 hours apart.</description>
    <arm_group_label>Placebo powder</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  obese (BMI +/- 30.0 kg/m2)&#xD;
&#xD;
          -  shift workers (shift work overnight (third shift) +/= 3 days/week for the past 3&#xD;
             months)&#xD;
&#xD;
          -  19-70 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patient history of gastrointestinal diseases except for hiatal hernia, GERD, or&#xD;
             hemorrhoids, mild gastrointestinal symptoms&#xD;
&#xD;
          -  elevated laboratory values from a comprehensive metabolic panel (CMP) and complete&#xD;
             blood count (CBC) with the exception of glucose (+/= 126 mg/dL; if elevated, confirmed&#xD;
             with HA1c of greater than or equal to 6.5%) and ALT, AST, or ALP over 2 times normal&#xD;
             levels (to allow for mild elevations resulting from fatty liver often seen in obese)&#xD;
             unless approved by study physician&#xD;
&#xD;
          -  currently pregnant or plans to become pregnant during the study as determined by&#xD;
             participant report&#xD;
&#xD;
          -  antibiotic use within the last 12 weeks prior to enrollment&#xD;
&#xD;
          -  presence of chronic metabolic disease (e.g., cardiovascular disease, diabetes, cancer)&#xD;
             or per physician discretion&#xD;
&#xD;
          -  recent (past 4 weeks) major change in dietary habits or a plan to have a major change&#xD;
             in dietary habits during the study&#xD;
&#xD;
          -  habitual blueberry consumption of more than 0.5 cups 2x/week or a 4-week washout&#xD;
             period if consumes&#xD;
&#xD;
          -  allergy or intolerance to blueberries&#xD;
&#xD;
          -  consumption of supplemental fiber, probiotics or prebiotics without an appropriate&#xD;
             4-week washout period&#xD;
&#xD;
          -  restrictive dietary patterns (e.g., ketogenic, Paleolithic) or a diet high in fiber&#xD;
             (+/= 14 g/1000 kilocalories) to increase study result generalizability to the U.S.&#xD;
             population (low-fiber diet), as well as provide another stimuli for gut leakiness&#xD;
&#xD;
          -  unwillingness to consent to the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heather E Rasmussen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Nebraska Lincoln</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Nebraska</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 15, 2019</study_first_submitted>
  <study_first_submitted_qc>April 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>June 9, 2021</last_update_submitted>
  <last_update_submitted_qc>June 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blueberry</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Intestinal permeability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronobiology Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

